However, at odds with IDO1 inhibitors, TDO inhibitors are effective in synergistic immunotherapy with ICIs even though there is little or no TDO expression in cancers, which may be because the inhibitor of TDO could block hepatic TDO to increase systemic Trp levels (60, 113). The gene discussed is TDO2; the disease is cancer.